These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38956425)

  • 1. Risk of stress cardiomyopathy associated with selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors: a real-world pharmacovigilance analysis.
    Tan B; Chen L; Yan S; Pan H; Zhang J; Wei H
    Sci Rep; 2024 Jul; 14(1):15167. PubMed ID: 38956425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin-Norepinephrine Reuptake Inhibitors and the Risk of AKI: A Cohort Study of Eight Administrative Databases and Meta-Analysis.
    Renoux C; Lix LM; Patenaude V; Bresee LC; Paterson JM; Lafrance JP; Tamim H; Mahmud SM; Alsabbagh MW; Hemmelgarn B; Dormuth CR; Ernst P;
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1716-22. PubMed ID: 26231193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postpartum Bleeding in Pregnant Women Receiving SSRIs/SNRIs: New Insights From a Descriptive Observational Study and an Analysis of Data from the FAERS Database.
    Perrotta C; Giordano F; Colombo A; Carnovale C; Castiglioni M; Di Bernardo I; Giorgetti F; Pileri P; Clementi E; Viganò C
    Clin Ther; 2019 Sep; 41(9):1755-1766. PubMed ID: 31371035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 Apr; 4(4):CD002919. PubMed ID: 25829028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System.
    Zhao Y; Zhang Y; Yang L; Zhang K; Li S
    Ann Pharmacother; 2024 Nov; 58(11):1105-1116. PubMed ID: 38407147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of abnormal uterine bleeding associated with high-affinity compared with low-affinity serotonin and norepinephrine reuptake inhibitors.
    Engler J; Filliter C; Montastruc F; Abenhaim H; Rej S; Renoux C
    J Affect Disord; 2024 Apr; 350():813-821. PubMed ID: 38246277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of serotonin-norepinephrine reuptake inhibitors versus selective serotonin reuptake inhibitors on cerebrovascular events.
    Lee YC; Lin CH; Lin MS; Lu Y; Chang CH; Lin JW
    J Clin Psychiatry; 2016 Jan; 77(1):e1-7. PubMed ID: 26845272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor use and risk of fractures: a new-user cohort study among US adults aged 50 years and older.
    Lanteigne A; Sheu YH; Stürmer T; Pate V; Azrael D; Swanson SA; Miller M
    CNS Drugs; 2015 Mar; 29(3):245-52. PubMed ID: 25708711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Antidepressant Medications With Incident Type 2 Diabetes Among Medicaid-Insured Youths.
    Burcu M; Zito JM; Safer DJ; Magder LS; dosReis S; Shaya FT; Rosenthal GL
    JAMA Pediatr; 2017 Dec; 171(12):1200-1207. PubMed ID: 29049533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension: a pharmacoepidemiological-pharmacodynamic study.
    Montastruc JL; Rousseau V; de Canecaude C; Roussin A; Montastruc F
    Eur J Clin Pharmacol; 2020 Sep; 76(9):1321-1327. PubMed ID: 32483650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apathy symptoms induced by low-dose venlafaxine: Two cases.
    Sato S; Sodeyama N; Matsuzaki A; Shiratori Y
    Neuropsychopharmacol Rep; 2020 Jun; 40(2):196-197. PubMed ID: 32267090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hyponatremia associated with SSRI/NRSI: Descriptive and comparative epidemiological study of the incidence rates of the notified cases from the data of the French National Pharmacovigilance Database and the French National Health Insurance].
    Revol R; Rault C; Polard E; Bellet F; Guy C
    Encephale; 2018 Jun; 44(3):291-296. PubMed ID: 29248119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
    Alrasheed M; Hincapie AL; Guo JJ
    J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of adverse events and comparative tolerability of selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for the treatment of anxiety, obsessive-compulsive, and stress disorders: a systematic review and network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Frozi J; Spanemberg L; Manfro GG; Cortese S; Cuijpers P; Pine DS; Salum GA
    Psychol Med; 2023 Jul; 53(9):3783-3792. PubMed ID: 37278215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials.
    Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC
    Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrovascular, Cardiovascular, and Mortality Events in New Users of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors: A Propensity Score-Matched Population-Based Study.
    Leong C; Alessi-Severini S; Enns MW; Nie Y; Sareen J; Bolton J; Prior HJ; Chateau D
    J Clin Psychopharmacol; 2017 Jun; 37(3):332-340. PubMed ID: 28383363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Effects of Selective Serotonin (and Noradrenaline) Reuptake Inhibitors on the Risk of Dementia in Patients with Depression.
    Kostev K; Bohlken J; Jacob L
    J Alzheimers Dis; 2019; 69(2):577-583. PubMed ID: 31104029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
    CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.